

Opinion Article

Current updates on in vitro dissolution testing for immediate release oral dosage forms

Comment [T1]: Check Authors Guidelines, Font etc.

Abstract:

Immediate-release oral dosage forms, also known as IR dosage forms, have become a popular choice for administering medication due to their ability to dissolve at an accelerated rate. This means that the medication is quickly released into the bloodstream, providing fast relief to patients. In the formulation development process, dissolution is a crucial aspect to consider as it can provide valuable information for quality control. In vitro dissolution testing, a laboratory method that simulates the dissolution of medication in the body, can offer insight into various stages of drug development.

Comment [T2]: Add Aims, Study design, Methodology, Results, Conclusion.

From a regulatory perspective, the review of preclinical and clinical data is greatly facilitated by the validation of dissolution for the product. In some cases, it may even be appropriate to use dissolution test results to evaluate the biopharmaceutical implications of a product change. This type of testing helps to ensure that the medication is not only effective, but also safe and reliable for patients.

In vitro dissolution testing can be used to evaluate a variety of factors including the rate of dissolution, the amount of medication released, and the effect of different formulations on dissolution. This can help researchers and manufacturers to optimize the formulation of the medication and ensure that it meets the necessary standards for efficacy and safety.

In conclusion, in vitro dissolution testing is an essential tool for evaluating the quality and performance of immediate-release oral dosage forms. It provides valuable information for the development and regulatory approval of medication, and can help to ensure that patients receive safe and effective treatment.

Key Words: BCS class, in vitro dissolution, FDA, EMA, immediate release dosage forms

Comment [T3]: Check format

Introduction:

Comment [T4]: CAP letters

Immediate drug release dosage forms disintegrate rapidly after administration with an increased rate of dissolution [1]. In the formulation of the tablet, super disintegrants such as croscarmellose, sodium starch glycolate, crospovidone, etc., play a fundamental role [2, 3]. These super disintegrants allow immediate disintegration of the tablet after administration in the stomach [2]. In this dosage form, 70%-85% of the indicated dose dissolves within 30 minutes [4]. This class is beneficial when an immediate onset of action is needed for therapeutic effect [5]. Usually, immediate-release dosage forms dissolve or disperse in a single action according to a first-order kinetics profile [6]. This demonstrates that the drug is initially released very rapidly and then travels through the mucosal membrane into the body, reaching its maximum plasma concentration (termed C_{max}) in a relatively short amount of time (termed t_{max}) [7].

Comment [T5]: Check format

The drug product release rates depend on the high solubility of the drug substance [8]. For immediate-release dosage form, drug products containing highly soluble drug substances may release at least 70% (preferably 80%) of the active ingredient within 30 minutes [9]. Immediate-release dosage forms formulated with poorly soluble active pharmaceutical ingredients (APIs) frequently require the use of surfactants to ensure complete release within 60 minutes [10].

Immediate-release dosage forms are designed to disintegrate quickly into smaller granules and then disaggregate into fine particles. The dissolution media is exposed to a larger surface area, resulting in a faster dissolution rate [11]. For poorly soluble immediate-release drug substances, excipients are used to facilitate disintegration (disintegrants) and disaggregation (surfactants) [12].

Dissolution is the method by which a solid drug enters the solvent phase to form a solution [13]. In vitro dissolution testing is performed throughout drug product development to facilitate formulation process development and to control product quality [10, 14-18]. The purpose of dissolution testing can provide information regarding the rate and extent of drug absorption in the body, and it can also examine the impact of drug substance biological properties and formulation principles on the release qualities of a drug product [19]. For the development and approval of generic dosage forms, in vitro dissolution testing is a key necessity [20]. Bioavailability and therapeutic effectiveness depend on how well a drug dissolves [21]. The purpose of in vitro dissolution testing is to determine the variables that influence the rate and

extent of drug substance release from the finished dosage form [14-18, 20]. Dissolution testing is rigorously used for stability and quality control purposes for different dosage forms [22]. It is employed to assist formulations and thereby select excipients for the formulations with the aim of selecting the most suitable and reproducible release profile [23]. If the dissolution test is not conducted under the required conditions, it may be difficult to predict the in vivo performance of the drug product [24].

The Food and Drug Administration (FDA) issued four guidance documents about in vitro dissolution and the regulatory implications of its application [25]. The first guidance outlines FDA requirements for immediate release dosage form dissolution and statistical methods for comparing dissolution characteristics [26]. FDA issued two guidelines on scale-up and postapproval modifications for immediate-release dosage forms [27]. These guidelines explain the types of information required for manufacturing modification approval [25]. The publication of these guidelines highlighted the FDA's substantial reliance on in vitro dissolution to rule out bioequivalence and confirmed the use of in vitro dissolution as a replacement for in vivo bioequivalence [28].

The European Medicines Agency (EMA) has published specific guidelines for immediate-release (IR) dosage forms [29]. This guideline is known as "the IR guideline" since it focuses on active chemical components in oral immediate-release (IR) formulations with systemic action [29, 30]. The European Medicines Agency (EMA) also issued a guideline for in vitro dissolution testing where the suitability of the dissolution method and the specifications for in vitro dissolution of orally administered generic drug products with immediate release characteristics are discussed [31]. The most recent approach by both the FDA and the EMA is to provide product-specific recommendations on the design of bioequivalence studies [32].

Comment [T6]: Add Specific objective

Test conditions:

Comment [T7]: Give number, Methods ?

Dissolution apparatus and agitation rate:

Generally, there are seven types of USP apparatuses that can be used within a regulatory environment to analyze the release of drug substances from a finished dosage form [19, 33]. USP Apparatus 1, the basket, and USP Apparatus 2, the paddle, are more commonly used for the

evaluation of in vitro dissolution of immediate-release solid oral dosage forms [34, 35]. Table 1 describes the comparison between these two USP apparatuses [36, 37].

Table 1. Comparison of USP Dissolution Apparatuses.

USP Apparatus	Apparatus Name	Agitation Rate	Dosage Form
I	Basket Method	50-100 rpm	Solid oral dosages forms like capsules or tablets
II	Paddle Method	50-75 rpm 25-50 rpm	Solid oral dosages forms like capsules or tablets, Suspensions

Comment [T8]: Give some examples

Table 1 shows the agitation speeds recommended by FDA. During the method development, the appropriateness of the agitation speed should be examined for each drug product formulation. An excessive agitation rate might result in foaming, which can lead to a failure to differentiate between formulations that are not equivalent [38].

But in some cases, USP apparatus three may also be used for the dissolution testing of IR products for highly soluble drugs, for example, metoprolol and ranitidine, as well as for some IR products of poorly soluble drugs, such as acyclovir. It is demonstrated that, with the proper agitation rate, USP apparatus three can generate dissolution profiles comparable to USP apparatus 2 [39].

Dissolution media:

The selection of dissolution medium in the development of dissolution methods can be arbitrary at times [40]. The selection of dissolution media depends on the solubility and stability of the drug substance, formulation, and component interactions [40]. In the case of dissolution studies, the media consist of acidic or basic solutions, buffers, surfactants, and surfactants with acid or buffers [41]. Media containing bile salts and other relevant physiologically based components, commonly referred to as relevant media, can be applied in regulatory tests but are mainly used as research tools or in vitro–in vivo correlation studies [42].

During the development of dissolution testing methods, the BCS (Biopharmaceutical Classification System) classification system can assist in determining the process/formulation

variations [43]. Immediate-release solid oral dosage forms consisting of highly soluble compounds such as BCS class I (high solubility, high permeability) or BCS class III (High solubility and low permeability), which achieve $\geq 85\%$ dissolved in 500 mL of 0.01 N HCl and agitation rate is either 30 min (BCS class I) or 15 min (BCS class III) [10]. BCS class II (low solubility, high permeability) and BCS class IV (low solubility, low permeability) drugs are mainly induced by pH and the type or nature of surfactant [40]. The use of various excipients may affect the solubility and permeability of these drugs [44]. The use of suitable surfactants, such as sodium lauryl sulfate (SLS), is believed to increase the solubility of the drug substance [44]. Classification of drug substances based on the Biopharmaceutics Classification System is shown in Table 02 [45], and The requirements of a dissolution media are shown in Table 03.

Table 2. Classification of drug substances based on the Biopharmaceutics Classification System

	High Solubility	Low Solubility
High Permeability	BCS Class 1	BCS Class 2
Low Permeability	BCS Class 3	BCS Class 4

Table 03: The requirements of a dissolution media

Requirements	Description
Buffer selection	The selected buffer should have the ability to maintain a constant PH throughout the dissolution test duration. In the case of weak acids or weak bases drug substance, the pH of the media can change as the drug substance dissolves. it is necessary to select the types of buffer and the amount of buffer to ensure the necessary buffer capacity [46].
pH	pH influences drug solubility and dissolution rate. The selection of pH depends on the drug substance. If the drug is weak acids, then the dissolution rate increases with an increase in pH, and if the drug is weak bases, the dissolution rate increases with a decrease in pH [47].
Media Volume	Typical media volumes are 500 ml, 900 ml, or 1000 ml for USP apparatus 1 and 2 [48].
Sink conditions	It is the ability of the dissolution media to dissolve at least three times the

	amount of drug that is present in the dosage form. Using sink conditions in the in-vitro dissolution test makes the test more robust and biologically relevant [49].
Surfactant	Surfactants are used to enhance the solubility or wettability of a drug. Surfactants minimize solution and surface interfacial tension by replacing water molecules on the surface [50]. For acidic drugs, media with cationic surfactants are better able to separate dissolution rates than media with other types of surfactants [51]. In addition, it is crucial to carefully consider the interactions among the ions and the type of surfactant used when dissolution media are selected. For example, potassium ions can react with SLS, making an insoluble product [52].
Common ion effect	The presence of a common ion can decrease the solubility of the drug substance. So the absence of a common ion should be ensured in dissolution media [53].
Deaeration	Gases dissolved in the dissolution media impact dissolution results. Degassing the media before use is required in this case. However, there are many methods and techniques available for removing air bubbles from the media [54, 55].

Dissolution temperature:

Generally, dissolution tests are conducted at 37°C to replicate normal human body temperature [56]. For immediate-release dosage forms, dissolution tests should be carried out at 37±0.5°C [57].

Sampling time points/ volume/ replenishment:

For immediate release, the sampling time points will typically be 15, 30, 45, and 60 minutes. When disintegration is rapid, the sampling time points are considered as 5 minutes and 10 minutes [58].

How to validate in vitro dissolution testing for a certain product?

Validation is performed to ensure that a method or procedure achieves its intended purpose.[59]. For immediate release, dosage form method validation was performed according to the USP and the International Conference on Harmonization (ICH) requirements [60-62]. Validation of the dissolution method includes the dissolution steps and the analytical endpoint. Dissolution steps are the release of a drug substance from the formulation of the product into the dissolution medium like performance evaluation parameters such as precision, linearity, repeatability, reproducibility, the limit of quantitation, etc., and the analytical endpoint includes the sample handling and the analytical methods that are used to determine the amount of drug substance dissolved during the dissolution step such as spectroscopic or chromatographic (HPLC and/or GC) [63-65]. Furthermore, the dissolution method should be capable of distinguishing between acceptable and unacceptable batches [66].

How to set an in vitro specification for in vitro dissolution testing for a certain product?

The in vitro dissolution test is thought to be a surrogate for the in vivo dissolution test. It will affect pharmacokinetic behavior, which is a substitute for clinical effectiveness [45]. The dissolution specification is specified in terms of the quantity (Q) of active substance dissolved in a specified time, represented as a percentage of the content stated on the product label [67]. When the test conditions for dissolution have been determined, a suitable dissolution specification should be established. The specification should be written in such a way that compliance with batches may be expected during routine production and testing [68]. Establishing appropriate dissolution specifications will ensure that the dosage form is manufactured consistently and successfully throughout the product's life cycle and that each dosage unit within a batch has the same pharmaceutical qualities that relate to those that have been shown to have an adequate safety and efficacy profile [25].

The function of the release specification

The dissolution specification for product release or shelf-life stability of a pharmaceutical product includes both the validated test method and the acceptance criteria for the test [69]. The expected acceptability criteria vary depending on the dosage form and must be justified in relation to in vivo performance, processing factors, and the outcomes of long-term stability tests

[48, 63]. The objective is to assure consistent performance from lot to lot over the life of the product, and it may be beneficial for showing product equivalence during scale-up or justifying specific postapproval adjustments [48]. The acceptance criteria are established based on a comprehensive examination of the dissolution data collected during development, including data from stability tests, with a focus on the testing of products used in clinical investigations [70].

Method Validation:

The validation of a dissolution test technique requires assessing the test's operational parameters as well as the acceptability of the analytical finish. The purpose is to demonstrate the method's capability to detect variations in the test product, which is significant enough to impact in vivo performance. The level of validation may vary depending on the stage of development. When the product is planned for commercialization, new elements or stricter criteria may be implemented. [70, 71].

Acceptance Criteria:

For immediate-release drugs, the acceptance criterion is usually a minimum amount of drug released (Q) at a single time point (usually less than or equal to 60 minutes). Typical release times for fast-acting dosage forms are 15 or 30 minutes. Products that release more slowly may need a second-time point, like an initial time point of 15 minutes and a second-time point at a later time, to make sure they release everything they are required to. The acceptance criteria chosen must be able to distinguish between batches that are non-bioequivalent and batches that expose the limits of acceptable process parameters [72-74].

Considerations for generic products:

For generic products, the dissolution specifications depend on some parameters, for example, dissolution profiles and data of the batches of the dosage form that shows similar acceptance criteria during in vivo bioequivalence studies. Once a dissolution specification has been established for the generic product based on the batch employed in the in vivo bioequivalence study, the generic product must adhere to that specification throughout its shelf life [20, 75, 76].

Scale-Up and Postapproval Changes

When a new drug product is developed, the batch sizes that are used in early human studies are generally small. With time the batch sizes are increased, which is called scale-up. The scale-up

process and the changes that are made after approval of the manufacturing process, formulation of the drug, batch size, manufacturing equipment, or change of site have known as Scale-Up and Postapproval Changes or SUPAC [77, 78]. The first SUPAC guidelines for immediate-release oral solid dosage formulations were issued in 1995. (SUPAC-IR) [79]. Primarily, SUPAC-IR was intended to reduce the regulatory burden of the industry when making postapproval changes while still maintaining formulation quality and therapeutic product performance. Among the postapproval modifications authorized by SUPAC-IR were changes in the formulation's ingredients and composition, manufacturing site, batch size, manufacturing equipment, and manufacturing method [80]. The guidance set levels of changes based on susceptible risk are to happen and how postapproval changes could affect the safety and effectiveness of a drug product [81-83].

Biowaiver Considerations

A biowaiver explains that in vivo bioavailability and/or bioequivalence studies may be waived [84]. Instead of doing expensive and time-consuming "in vivo" studies, a "dissolution test" could be used to decide if the two pharmaceutical products are the same. Even if a complete clinical investigation is conducted, the likelihood of therapeutic inequivalence between two immediate-release drugs cannot be minimized. The objective of biowaiver guidance is to decrease bioequivalence risk to a tolerable level [8, 85]. In August 2000, the FDA provided industry guidelines on waivers of in vivo bioavailability and bioequivalence studies for IR solid oral dosage forms based on the BCS [32]. BCS guidance suggests that sponsors may obtain biowaivers for highly soluble and highly permeable drug compounds (Class I) in IR solid oral dosage forms with rapid in vitro dissolution if the following conditions are met: 1) The medicine must be gastrointestinally stable, 2) excipients used in the IR solid oral dosage forms have no major effect on the rate and extent of oral drug absorption; 3) the medication must not have a narrow therapeutic index; and 4) the product is not developed for oral absorption [86-88].

Conclusion:

In vitro dissolution is gaining importance in a variety of regulatory aspects. Recently, regulatory agencies in the European Union (EU) and the United States (US) have been at the forefront of dissolution guidelines. However, recent trends indicate a rise in dissolution similarity criteria from regulatory authorities around the world. This results in different dissolution profile

standards and a substantial amount of unnecessary and duplicated work that does not contribute to the safety or efficacy of the product.

References:

1. Nyol S, Gupta MJJoDD, Therapeutics. Immediate drug release dosage form: a review. 2013;3(2).
2. Sharma N, Pahuja S, Sharma NJJPSR. Immediate release tablets: A review. 2019;11:3607-18.
3. Neha D, Kamini KM, Neeraj P, Manmohan S, Kamal V, Neeraj SJWJoP, et al. Immediate release tablets: A review. 2017;6(4):595-611.
4. Redigueri CF, Porta V, Nunes DS, Nunes TM, Junginger HE, Kopp S, et al. Biowaiver monographs for immediate release solid oral dosage forms: metronidazole. 2011;100(5):1618-27.
5. Buwade P, Jadiya S, Shukla T, Upmanyu DNJWJoPR. Advantages of immediate release tablets over the other tablet forms. 2015;4(11):757-80.
6. Rahul M, Patil S, Shetkar M, Chavan D, Bhagwat PJP. A review on immediate release drug delivery systems. 2014;2(8):95-109.
7. Perrie Y, Rades T. FASTtrack Pharmaceuticals: Drug Delivery and Targeting: Pharmaceutical press; 2012.
8. Gupta E, Barends D, Yamashita E, Lentz K, Harmsze A, Shah V, et al. Review of global regulations concerning biowaivers for immediate release solid oral dosage forms. 2006;29(3-4):315-24.
9. GL19 VJCFVM. Guidance for Industry. 2002.
10. Hermans A, Abend AM, Kesisoglou F, Flanagan T, Cohen MJ, Diaz DA, et al. Approaches for establishing clinically relevant dissolution specifications for immediate release solid oral dosage forms. 2017;19(6):1537-49.
11. Fortunato DJDT. Dissolution method development for immediate release solid oral dosage forms. 2005;12(3):11.
12. Bredael GM, Liang S, Hahn DJDT. A strategy for quality control dissolution method development for immediate-release solid oral dosage forms. 2015;22:10-6.
13. Banakar UV. Pharmaceutical dissolution testing: CRC Press; 1991.
14. Nandi T, Rahman A, Jahan N, Islam R, Pavel O. Determination of in vitro release kinetics of metformin hydrochloride from six brands of metformin hydrochloride tablets available in Bangladesh using water media: A UV spectroscopic analysis. Spec J Med Res Health Sci. 2017;2(2):8-16.
15. Nandi T, Rahman MA, Hossain MK, Pavel OF, Sultana R. In-vitro comparative dissolution study of different brands of Ranitidine hydrochloride tablets available in Bangladesh. International Journal of Sciences and Applied Research. 2016;3(7):14-20.
16. Nandi T, Rahman MA, Islam RS, Mozumder SH, Hasan KS, Rahman M, et al. In-Vitro Release Kinetics of Clonazepam from Five Brands of Clonazepam Available in Bangladesh Using UV Spectroscopic Analysis in Deionized Water Media. 2017.
17. Nandi T, Rahman MA, Pavel OF, Liza SA, Huq MA, Haque MJ, et al. Impact of Calcium-Vitamin D Supplements on the Dissolution Pattern of Ranitidine Hydrochloride Tablets: An in vitro Dissolution Study using UV Spectroscopy. Journal of biomedical and pharmaceutical research. 2016;5(5):17-21.
18. Tamanna S, Nandi T, Shahriar R, Barek MA, Zamsad M. In-vitro Comparative Dissolution Study of Different Brands of Levocetirizine Dihydrochloride Available in Bangladesh. International Journal of Innovation and Applied Studies. 2019;26(2):556-61.

19. Lee SL, Raw AS, Yu L. Dissolution testing. Biopharmaceutics applications in drug development: Springer; 2008. p. 47-74.
20. Anand O, Yu LX, Conner DP, Davit BMJTAj. Dissolution testing for generic drugs: an FDA perspective. 2011;13(3):328-35.
21. Dressman JB, Krämer J. Pharmaceutical dissolution testing: Taylor & Francis Boca Raton, FL.; 2005.
22. Kraemer J, Gajendran J, Guillot A, Schichtel J, Tuereli AJJoP, Pharmacology. Dissolution testing of orally disintegrating tablets. 2012;64(7):911-8.
23. Storey DEJDIJ. The role of dissolution testing in the design of immediate release dosage forms. 1996;30(4):1039-44.
24. Dressman JB, Amidon GL, Reppas C, Shah VPJPr. Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms. 1998;15(1):11-22.
25. Marroum PJJDT. History and evolution of the dissolution test. 2014;21(3):11-6.
26. Food, Administration D, Food, Evaluation DAJcFd, Research UDoH, Services H. Guidance for industry: dissolution testing of immediate release solid oral dosage forms. 1997.
27. Forms IRSODJVDI, Documentation IVB. Scale-Up and Postapproval Changes: Chemistry, Manufacturing, and Controls. 1995;415.
28. SUPAC-MR FJVDI, . IVBD. Modified Release Solid Oral Dosage Forms: Scale-Up and Post-Approval Changes: Chemistry, Manufacturing, and Controls. 1997.
29. Verbeeck RK, Musuamba FTJJoP, Sciences P. The revised EMA guideline for the investigation of bioequivalence for immediate release oral formulations with systemic action. 2012;15(3):376-88.
30. Morais JAG, Lobato MdRJB, pharmacology c, toxicology. The new European Medicines Agency guideline on the investigation of bioequivalence. 2010;106(3):221-5.
31. Kanojiya S, Patel N, Patel RJ, Patel AAJJODRA. Comparison of dissolution profile for immediate-release dosage form for US and Europe. 2022;10(2):35-8.
32. Davit BM, Kanfer I, Tsang YC, Cardot J-MJTAj. BCS biowaivers: similarities and differences among EMA, FDA, and WHO requirements. 2016;18(3):612-8.
33. Shah VP, Gurbarg M, Noory A, Dighe S, Skelly JPJops. Influence of higher rates of agitation on release patterns of immediate-release drug products. 1992;81(6):500-3.
34. Shiu GKJDIJ. Dissolution methodology: apparatus and conditions. 1996;30(4):1045-54.
35. Qiu S, Wang K, Li MJDT. In vitro dissolution studies of immediate-release and extended-release formulations using flow-through cell apparatus 4. 2014;21:6-16.
36. Guidance FJF, Drug Administration CfDE, Research. Guidance for industry: Dissolution testing of immediate release solid oral dosage forms. US Department of Health and Human Services. 1997.
37. Hasan MM, Rahman MM, Islam MR, Hasan H, Hasan MM, Rashid HAJTPIJ. A key approach on dissolution of pharmaceutical dosage forms. 2017;6(9):168-80.
38. Salve PM, Sonawane SV, Patil MB, Surawase RK. Dissolution and Dissolution Test Apparatus: A Review. 2021.
39. Yu LX, Wang JT, Hussain ASJAP. Evaluation of USP apparatus 3 for dissolution testing of immediate-release products. 2002;4(1):1-5.
40. Fotaki N, Brown W, Kochling J, Chokshi H, Miao H, Tang K, et al. Rationale for selection of dissolution media: three case studies. 2013;20:6-13.
41. Pharmacopeia UJW, DC. 32-NF-27, the United States Pharmacopeial Convention. 2009:2701.
42. Fotaki N, Vertzoni MJTODDJ. Biorelevant dissolution methods and their applications in in vitro-in vivo correlations for oral formulations. 2010;4(1).
43. Saxena S, Jain SJAJoP, Technology. A review on biopharmaceutical classification system. 2019;9(4).

44. Farah K, Syed MFH, Madiha M, Rabia N, Sana G, Iyad NM, et al. Comparative analysis of biopharmaceutic classification system (BCS) based bioequivalence protocols to validate equivalence of a multisource product. 2020;14(7):212-20.
45. Limberg J, Potthast HJB, disposition d. Regulatory status on the role of in vitro dissolution testing in quality control and biopharmaceutics in Europe. 2013;34(5):247-53.
46. Mauger JWJD. Physicochemical properties of buffers used in simulated biological fluids with potential application for in vitro dissolution testing: A mini-review. 2017;24(3):38-51.
47. Scott N, Patel K, Sithole T, Xenofontos K, Mohylyuk V, Liu FJJOP. Regulating the pH of bicarbonate solutions without purging gases: Application to dissolution testing of enteric coated tablets, pellets and microparticles. 2020;585:119562.
48. Nissankarao S, Kallam V, Bhimavarapu RJIJPRD. Dissolution method development and validation: a review. 2013;5:106-12.
49. Polli JEJTAJ. A Simple One-Parameter Percent Dissolved Versus Time Dissolution Equation that Accommodates Sink and Non-sink Conditions via Drug Solubility and Dissolution Volume. 2023;25(1):1-16.
50. Balakrishnan A, Rege BD, Amidon GL, Polli JEJops. Surfactant-mediated dissolution: contributions of solubility enhancement and relatively low micelle diffusivity. 2004;93(8):2064-75.
51. Park S-H, Choi H-KJjop. The effects of surfactants on the dissolution profiles of poorly water-soluble acidic drugs. 2006;321(1-2):35-41.
52. Ropers M, Czichocki G, Brezesinski GJTJoPCB. Counterion effect on the thermodynamics of micellization of alkyl sulfates. 2003;107(22):5281-8.
53. Shin ES, Kim K, Oh SH, Cho WIJCC. Polysulfide dissolution control: the common ion effect. 2013;49(20):2004-6.
54. Gao Z, Moore TW, Doub WH, Westenberger B, Buhse LFJJops. Effects of deaeration methods on dissolution testing in aqueous media: a study using a total dissolved gas pressure meter. 2006;95(7):1606-13.
55. Qureshi S, McGilveray IJDD, pharmacy i. A critical assessment of the USP dissolution apparatus suitability test criteria. 1995;21(8):905-24.
56. Riley T, Christopher D, Arp J, Casazza A, Colombani A, Cooper A, et al. Challenges with developing in vitro dissolution tests for orally inhaled products (OIPs). 2012;13(3):978-89.
57. Shohin I, Grebenkin DY, Malashenko E, Stanishevskii YM, Ramenskaya GJDT. A brief review of the FDA dissolution methods database. 2016;23(3):6-10.
58. Gray VA, Zheng JY, Sesi NNJF, Products ADfL-DOD. In vitro dissolution testing and method development. 2009:265.
59. Likar MD, Mansour HL, Harwood JWJop, analysis b. Development and validation of a dissolution test for a once-a-day combination tablet of immediate-release cetirizine dihydrochloride and extended-release pseudoephedrine hydrochloride. 2005;39(3-4):543-51.
60. Marles RJ, Barrett ML, Barnes J, Chavez ML, Gardiner P, Ko R, et al. United States pharmacopeia safety evaluation of Spirulina. 2011;51(7):593-604.
61. Dayyih WA, Hamad M, Mallah E, Abu Dayyih A, Awad RJI. METHOD Development and Validation of Vildagliptin and Metformin HCl in Pharmaceutical Dosage form by Reversed Phase-High Performance Liquid Chromatography (RP-HPLC). 2018;9(7):2965-72.
62. Rambla-Alegre M, Esteve-Romero J, Carda-Broch SJJCA. Is it really necessary to validate an analytical method or not? That is the question. 2012;1232:101-9.
63. Vaghela B, Kayastha R, Bhatt N, Pathak N, Rathod DJJoaps. Development and validation of dissolution procedures. 2011(Issue):50-6.

64. Frick A, Möller H, Wirbitzki EJEjop, biopharmaceutics. Biopharmaceutical characterization of oral immediate release drug products. In vitro/in vivo comparison of phenoxymethylpenicillin potassium, glimepiride and levofloxacin. 1998;46(3):305-11.
65. Medina JR, Salazar DK, Hurtado M, Cortes AR, Dominguez-Ramirez AMJSPJ. Comparative in vitro dissolution study of carbamazepine immediate-release products using the USP paddles method and the flow-through cell system. 2014;22(2):141-7.
66. Chan CC, Pearson N, Rebelo-Cameirao A, Lee YJAMV, Verification IP. Dissolution method validation. 2004:51-66.
67. Suarez-Sharp S, Cohen M, Kesiosoglou F, Abend A, Marroum P, Delvadia P, et al. Applications of clinically relevant dissolution testing: workshop summary report. Springer; 2018.
68. Hayes S, Dunne A, Smart T, Davis JJops. Interpretation and optimization of the dissolution specifications for a modified release product with an in vivo–in vitro correlation (IVIVC). 2004;93(3):571-81.
69. Pepin XJ, Flanagan TR, Holt DJ, Eidelman A, Treacy D, Rowlings CEJMp. Justification of drug product dissolution rate and drug substance particle size specifications based on absorption PBPK modeling for lesinurad immediate release tablets. 2016;13(9):3256-69.
70. Long M, Chen Y. Dissolution testing of solid products. Developing solid oral dosage forms: Elsevier; 2009. p. 319-40.
71. Boudreau SP, McElvain JS, Martin LD, Dowling T, Fields SMJPT. Method validation by phase of development. 2004;28(11):54-66.
72. FDA UJcFDE, Research. Guidance for Industry, Waiver of in vivo bioavailability and bioequivalence studies for immediate release solid oral dosage forms based on a biopharmaceutics classification system. 2000.
73. Hofer JD, Gray VAJDT. Examination of selection of immediate release dissolution acceptance criteria. 2003;10(1):16-20.
74. Bioavailability FJcFDE, Research. bioequivalence studies for orally administered drug products—general considerations: guidance for industry. Rockville: FDA. 2003.
75. Meredith PAJDS. Generic drugs. 1996;15(4):233-42.
76. Kaur P, Jiang X, Duan J, Stier EJTAj. Applications of in vitro–in vivo correlations in generic drug development: case studies. 2015;17(4):1035-9.
77. Schwartz JBJPJoPS, Technology. SUPAC. 1996;50(2):67-.
78. Sharma P, Ganta S, Garg S. Scale-Up and Postapproval Changes (SUPAC) Regulations: John Wiley & Sons Limited; 2008.
79. Mendapara VP, Purohit P, Ashara KJIRPT. SUPAC of immediate release solid oral dosage form- eplerenone. 2013;2013(3):1-7.
80. Sah H-K, Park S, Yun M-O, Kang S-JJJoPI. Scrutiny Made to SUPAC-IR Dealing with Postapproval Changes in Immediate Release Solid Oral Dosage Forms. 2004;34(1):57-71.
81. Waterland NH, Kowtna CCJPPV. Change control and SUPAC. 2003:742-91.
82. NVN M. SCALE UP AND POSTAPPROVAL CHANGES (SUPAC) GUIDANCE FOR INDUSTRY: A REGULATORY NOTE. 2017.
83. Augsburg LL, Hoag SW. Pharmaceutical dosage forms-tablets: CRC press; 2016.
84. Karam RJPbDMK. Biowaivers: Criteria and requirements. 2015:1-11.
85. Faassen F, Vromans HJcP. Biowaivers for oral immediate-release products. 2004;43(15):1117-26.
86. Yu LX, Amidon GL, Polli JE, Zhao H, Mehta MU, Conner DP, et al. Biopharmaceutics classification system: the scientific basis for biowaiver extensions. 2002;19(7):921-5.

87. Van Oudtshoorn JE, García-Arieta A, Santos GML, Crane C, Rodrigues C, Simon C, et al. A survey of the regulatory requirements for BCS-based biowaivers for solid oral dosage forms by participating regulators and organisations of the international generic drug regulators programme. 2018;21:27-37.
88. Kalantzi L, Reppas C, Dressman J, Amidon G, Junginger H, Midha K, et al. Biowaiver monographs for immediate release solid oral dosage forms: Acetaminophen (paracetamol). 2006;95(1):4-14.

Comment [T9]: Align references and check guidelines as per journal format.

UNDER PEER REVIEW